Results for tag: "Takhzyro"

Takhzyro (lanadelumab-flyo) is a monoclonal antibody used to treat hereditary angioedema (HAE), a rare and potentially life-threatening genetic disorder. It is the first and only approved therapy for HAE that prevents attacks by blocking the activity of the plasma kallikrein enzyme. Takhzyro is administered as a subcutaneous injection every two weeks. The Takhzyro market is a rapidly growing segment of the immune disorders drugs market. It is driven by the increasing prevalence of HAE, the availability of effective treatments, and the growing awareness of the condition. The market is expected to continue to grow in the coming years, driven by the increasing demand for HAE treatments and the development of new therapies. Companies in the Takhzyro market include Shire, CSL Behring, and Grifols. Shire is the manufacturer of Takhzyro, while CSL Behring and Grifols are both involved in the development and marketing of HAE treatments. Show Less Read more